Product Stewardship.

Product Stewardship Targets

Johnson Matthey remains committed to driving improvement in product sustainability and effective product stewardship in both the external supply chain and within our operations.

Our product stewardship targets are to:

  • Encourage the responsible management of substances throughout the supply chain.
  • Enhance product sustainability as part of our overall corporate sustainability programme with a particular focus on managing restricted substances, the use of optimisation strategies during new product introduction and the application of green chemistry principles in product design. This aligns with our commitment to avoid substances of concern in the development of new technologies and to phase out such substances in existing products wherever feasible.
  • Use systematic substance selection mechanisms to identify preferred alternatives in terms of human health and environmental safety.
  • Continue to improve the publicly available information on the health and environmental effect profiles of any chemical substances placed on the market and link this to updated risk management measures.
  • Promote the use of objective hazard ranking techniques and related exposure control targets for our chemical products and process intermediates. These will be applied in Johnson Matthey’s workplaces and more widely in our product stewardship and risk management activities throughout the supply chain.
  • During 2011/12 we will set new targets to further formalise product stewardship and sustainability reviews for both new and existing products. These systems will stipulate best practice guidelines and set schedules for product reviews at the pre-commercialisation stage and thereafter (at a frequency that is commensurate with the associated risk). This framework will be augmented by other group policies and guidelines on restricted substance management (for example, substances of concern) and on our hazard and risk assessment practices.
  • As part of our commitment to the safe management of chemicals throughout their life cycle, Johnson Matthey has commenced a voluntary programme to establish expanded product safety assessments for designated priority products. This aligns with the International Council of Chemical Associations’ (ICCA) best practices.

Animal Testing

In common with all companies developing and marketing chemical substances, Johnson Matthey is obliged by international legislation to make toxicity information available to assure product safety for humans, wildlife and the environment. If we have confirmed that suitable data does not already exist, we always attempt to limit testing and avoid redundant studies by undertaking collaborative work with industrial partners. If in vivo studies are unavoidable, it is ensured that such work complies with applicable laws, regulations, licensing and welfare codes. Johnson Matthey only uses fully accredited contract research organisations and does not undertake any in house testing. No vertebrate animal studies are permitted to be commissioned by our businesses until a full justification has been carefully considered and approved centrally at group level.

Johnson Matthey has adopted and embraced the ‘3Rs’ approach to enhance our reliance on properly validated alternative methods which reduce, refine or replace the use of animal testing. We place emphasis on applying the latest integrated testing strategies (e.g. in vitro assays, computer modelling of effects and test waiving requests). New 3R techniques are continuously tracked and implemented as they become endorsed by regulatory bodies. During 2010/11 Johnson Matthey has provided financial sponsorship for external educational programmes aimed at increasing awareness of these alternative approaches.

The group does not manufacture any cosmetics or consumer goods and any testing is therefore aligned to regulatory requirements for industrial substances. Any testing required as a result of the introduction of EU REACH regulation is minimised by working within industry consortia. In the context of regulatory regimes such as REACH, we follow best practice guidelines on reducing the need for in vivo studies.

Johnson Matthey shares current public and political concern over animal testing and we only commission studies when absolutely mandated by law and if no alternatives exist. We remain optimistic that advances in toxicology science will enable us to further reduce in vivo testing while continuing to protect human health and the environment.